Ładuje się......
Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis
Alemtuzumab is a selective humanized monoclonal antibody directed against the CD52 antigen, and has been found to be a powerful treatment for relapsing remitting multiple sclerosis. Alemtuzumab demonstrated high efficacy in several clinical studies. The risk of relapse and sustained accumulation of...
Zapisane w:
| Wydane w: | Ther Clin Risk Manag |
|---|---|
| Główni autorzy: | , , |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Dove Medical Press
2017
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5522829/ https://ncbi.nlm.nih.gov/pubmed/28761351 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S134398 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|